Emerging Targets in Gastrointestinal (Gastric & Gastroesophageal) Cancers – Clinical Brief #1 Posttest and Evaluation (ID: i832-1) Survey

Question Title

* 1. When would you request MSI/MMR diagnostic testing?

At diagnosis

Concurrent with chemo

Prior to 2L treatment

Question Title

* 2. In what cancer type would you opt to use a liquid biopsy?

Biliary

Colorectal

Gastric

Pancreatic

Question Title

* 3. Which biomarker can be optimally assessed using liquid biopsy?

HER2

MMR

MSI

PD-L1

Question Title

* 4. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 5. How many patients with GI cancer do you manage per week? 

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 6. Please select the option that best describes your practice:

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 7. After participating in this activity, how confident are you now in the management of patients with GI cancer in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity? 

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 9. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 10. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Increased familiarity with guideline-recommended biomarker testing

Increased familiarity with settings in which liquid biopsy may be beneficial

Increased familiarity with biomarker testing methods

Increased familiarity with biomarkers that can be assessed with liquid biopsy

Question Title

* 11. What barriers do you see to making changes in your practice? Please select all that apply. 

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer	Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer Strongly agree	Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer Agree	Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer Neutral	Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer Disagree	Select optimal testing methods and timing for patients diagnosed with gastric, gastroesophageal, and gastroesophageal junction cancer Strongly disagree
Select patients and incorporate liquid biopsy into clinical practice	Select patients and incorporate liquid biopsy into clinical practice Strongly agree	Select patients and incorporate liquid biopsy into clinical practice Agree	Select patients and incorporate liquid biopsy into clinical practice Neutral	Select patients and incorporate liquid biopsy into clinical practice Disagree	Select patients and incorporate liquid biopsy into clinical practice Strongly disagree
Assess testing methods and interpretation for currently approved molecular biomarkers	Assess testing methods and interpretation for currently approved molecular biomarkers Strongly agree	Assess testing methods and interpretation for currently approved molecular biomarkers Agree	Assess testing methods and interpretation for currently approved molecular biomarkers Neutral	Assess testing methods and interpretation for currently approved molecular biomarkers Disagree	Assess testing methods and interpretation for currently approved molecular biomarkers Strongly disagree

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating.

Strongly agree, Agree, Neutral, Disagree, Strongly disagree

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Faculty for this activity was effective	Faculty for this activity was effective Strongly agree	Faculty for this activity was effective Agree	Faculty for this activity was effective Neutral	Faculty for this activity was effective Disagree	Faculty for this activity was effective Strongly disagree
Content was scientifically rigorous and evidence based	Content was scientifically rigorous and evidence based Strongly agree	Content was scientifically rigorous and evidence based Agree	Content was scientifically rigorous and evidence based Neutral	Content was scientifically rigorous and evidence based Disagree	Content was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for GI (Gastric & Gastroesophageal) cancers.

Question Title

* 16. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 17. Request for CME Credit:

I participated in only part of the activity and claim 0.5 credit

I participated in only part of the activity and claim 0.25 credit

Question Title

* 1. When would you request MSI/MMR diagnostic testing?

Question Title

* 2. In what cancer type would you opt to use a liquid biopsy?

Question Title

* 3. Which biomarker can be optimally assessed using liquid biopsy?

Question Title

* 4. How many years have you been in practice?

Question Title

* 5. How many patients with GI cancer do you manage per week?

Question Title

* 6. Please select the option that best describes your practice:

Question Title

* 7. After participating in this activity, how confident are you now in the management of patients with GI cancer in your practice?

Question Title

* 8. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 9. Which of the following best describes the impact of this activity on your performance?

Question Title

* 10. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 11. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.After participating in today’s activity, I am now better able to:

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating. Strongly agree, Agree, Neutral, Disagree, Strongly disagree

Question Title

* 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for GI (Gastric & Gastroesophageal) cancers.

Question Title

* 16. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 17. Request for CME Credit:

Question Title

* 18. Address

* 5. How many patients with GI cancer do you manage per week? 

* 8. How committed are you to making changes in your practice based on your participation in this activity? 

* 11. What barriers do you see to making changes in your practice? Please select all that apply. 

* 12. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

* 13. Please rate your level of agreement by checking the appropriate rating.

Strongly agree, Agree, Neutral, Disagree, Strongly disagree